Data On Givosiran And Lumasiran Should Help The Alnylam Story

Even as Alnylam (ALNY) works toward its second commercial drug filing, questions remain about the safety and efficacy of givosiran, not to mention the platform as a whole. But with good full Phase III data on givosiran and encouraging open-label extension data on lumasiran over the last few days, the story has gotten a little better in my view. These shares still remain undervalued, but there remain numerous risks including FDA approval, the efficacy and safety of the lead pipeline candidates, competition, and challenges related to commercialization, including identifying patients and securing reimbursement.

Read more here:
Data On Givosiran And Lumasiran Should Help The Alnylam Story

The Motley Fool: Merck & Co., Inc. Cutting Its Losses, While Others Charge Toward RNAi

Sometimes success in business requires the ability to make decisions and zig while others are zagging. It is also important to know when to stop throwing good money after bad and call it a day. I believe those two bromides may offer some explanation for why Merck (NYSE: MRK  ) agreed to sell its Sirna assets to Alnylam Pharmaceuticals (NASDAQ: ALNY  ) for a small fraction of their purchase price at a time when others like Sanofi (NYSE: SNY  ) and Roche (NASDAQOTH: RHHBY  ) are increasing their spending and commitment to the space.

Click here to continue:
Merck & Co., Inc. Cutting Its Losses, While Others Charge Toward RNAi